RALA and chronic myelogenous leukemia, BCR-ABL1 positive: By contrast, the RalA+/+ CML-like cells with LSK phenotype accounted for only 7.72% (Figure 5A); this finding revealed that RalA overexpression in BMCs maintained an LSK cell phenotype.